High-nuclearity Luminescent Lanthanide Nanocages for Tumor Drug Delivery

18Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

There is an unmet need for easy-to-visualize drug carriers that can deliver therapeutic cargoes deep into solid tumors. Herein, we report the preparation of ultrasmall luminescent imine-based lanthanide nanocages, Eu60 and Tb60 (collectively Ln60), designed to encapsulate anticancer chemotherapeutics for tumor therapy. The as-prepared nanocages possess large cavities suitable for the encapsulation of doxorubicin (DOX), yielding DOX@Ln60 nanocages with diameters around 5 nm. DOX@Ln60 are efficiently internalized by breast cancer cells, allowing the cells to be visualized via the intrinsic luminescent property of Ln(III). Once internalized, the acidic intracellular microenvironment promotes imine bond cleavage and the release of the loaded DOX. DOX@Ln60 inhibits DNA replication and triggers tumor cell apoptosis. In a murine triple negative breast cancer (TNBC) model, DOX@Ln60 was found to inhibit tumor growth with negligible side effects on normal tissues. It proved more effective than various controls, including DOX and Ln60. The present nanocages thus point the way to the development of precise nanomedicines for tumor imaging and therapy.

Cite

CITATION STYLE

APA

Wang, S. Q., Wang, Y., Yang, X., Liu, Y., Li, H., Yang, Z., … Sessler, J. L. (2024). High-nuclearity Luminescent Lanthanide Nanocages for Tumor Drug Delivery. Angewandte Chemie - International Edition, 63(12). https://doi.org/10.1002/anie.202317775

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free